NCT00306514View on ClinicalTrials.gov

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Melanoma
Interventions
BIOLOGICAL

CYT004-MelQbG10

Trial Locations (1)

10117

Dept. of Dermatology, Venerology and Allergy, Berlin

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY

NCT00306514 - Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients | Biotech Hunter | Biotech Hunter